Cencora Inc (COR)

$324.80 +7.14 (2.25%)
Market Cap 63.18B
Revenue (ttm) 321.33B
Net Income (ttm) 1.55B
EPS (ttm) N/A
PE Ratio 19.44
Forward PE 18.07
Profit Margin 0.48%
Debt to Equity Ratio 3.78
Volume 1,266,100
Avg Vol 1,393,446
Day's Range N/A - N/A
Shares Out 194.53M
Stochastic %K 72%
Beta 0.72
Analysts Strong Sell
Price Target $412.92

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distr...

Industry: Medical Distribution
Sector: Healthcare
Phone: 610 727 7000
Address:
1 West First Avenue, Conshohocken, United States
TalkMarkets
TalkMarkets Mar. 25 at 5:04 PM
The Growth Of Big Business: 1900-2020 $XOM $COR https://talkmarkets.com/article/b2346cd0-4c2c-45eb-9238-d7426cc25691
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 9:17 PM
$COR RSI: 24.02, MACD: -8.7204 Vol: 17.26, MA20: 350.55, MA50: 353.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 23 at 10:38 PM
$COR Share Price: $320.66 Contract Selected: Aug 21, 2026 $320 Calls Buy Zone: $39.10 – $48.30 Target Zone: $65.63 – $80.22 Potential Upside: 59% ROI Time to Expiration: 150 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CrazyChief
CrazyChief Mar. 23 at 8:47 PM
$OTLK $COR LET'S GO!! CENCORA PLEASE SCOOP UP OUTLOOK THERAPEUTICS!! 🙏🙏
0 · Reply
prismmarketview
prismmarketview Mar. 23 at 2:48 PM
$COR 🔵 Cencora just signed a $1.1B deal to acquire EyeSouth Partners' retina business — folding 400+ new physicians into its Retina Consultants of America platform. The numbers: physician count goes from ~300 to 700+. Retina market share jumps from ~1-2% to 3%+. Deal expected to be EPS-accretive within 12 months of close. Guidance reaffirmed. No FY2026 close assumed — so any contribution is pure upside to current estimates. Specialty care consolidation is real and $COR is leading it. 👁️ Regulatory approval pending. Not financial advice. https://prismmarketview.com/cencora-bets-1-1-billion-on-retina-care-and-the-math-makes-sense/
0 · Reply
50bps
50bps Mar. 17 at 1:53 PM
$COR 👀
1 · Reply
Ro_Patel
Ro_Patel Mar. 9 at 6:25 PM
Health Secretary RFK Jr plans to loosen restrictions on some peptides that the FDA previously prohibited compounding pharmacies from producing Kennedy wants to unban 14 of the 19 peptides that were placed on an FDA "do not formulate" list in 2023 Many physicians argue that many of them don't have sufficient evidence behind them to prove that they're safe & that they work https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks When the FDA added those peptides to its do-not-compound list, wellness entrepreneurs & compounding pharmacies pushed back, w/ some filing lawsuits against the FDA Kennedy blamed litigation for allowing him to only reinstate 14 of the 19 peptides that had been added to the list $MCK $COR $HIMS - $IPN $CTLT
1 · Reply
IN0V8
IN0V8 Mar. 3 at 6:09 PM
$COR 3/2 Buy Leerink Partners raises target price to $447 from $410
0 · Reply
RenkoTradingSystem
RenkoTradingSystem Feb. 28 at 12:11 PM
$COR 195 MIN 1% Renko Chart Only buy on the 1st and 2nd Green Bricks. 1/2 position on the 1st Green Brick. And the balance on the 2nd Green Brick. 1st 1/2 Entry: Pullback had at least 2-3 Red Bricks (clean, not choppy). 1st Green Brick appears. Stock Price is above EMA(20) and is rising. (Confirm at Daily Close; buy next Open) > Never enter on the 3rd Green Brick. 2nd Half Entry > Triggered within 2 Green Bricks of the first entry if no Red Bricks have appeared and EMA(20) is still rising. > If you miss buying on the 1st Green Brick: A 66% position on the 2nd Green Brick. (Confirm at Daily Close; buy next Open)
0 · Reply
DanFitz
DanFitz Feb. 28 at 2:12 AM
Here's your trade on Cencora $COR https://youtu.be/jbX0V_yHLHA
0 · Reply
Latest News on COR
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

Apr 1, 2026, 4:30 PM EDT - 3 days ago

Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

Cencora to buy retina business of EyeSouth Partners for $1.1 billion

Mar 23, 2026, 7:06 AM EDT - 13 days ago

Cencora to buy retina business of EyeSouth Partners for $1.1 billion

Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business

Mar 23, 2026, 7:00 AM EDT - 13 days ago

Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business

Cencora Announces Financial Leadership Transition

Mar 17, 2026, 8:30 AM EDT - 19 days ago

Cencora Announces Financial Leadership Transition

Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 5:30 PM EDT - 25 days ago

Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript

Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 11:30 AM EDT - 26 days ago

Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Cencora's animal health unit to merge with Covetrus in $3.5 billion deal

Feb 18, 2026, 7:09 AM EST - 6 weeks ago

Cencora's animal health unit to merge with Covetrus in $3.5 billion deal

Covetrus and MWI Animal Health to Merge

Feb 18, 2026, 7:00 AM EST - 6 weeks ago

Covetrus and MWI Animal Health to Merge

Cencora Closes $3.0 Billion Senior Notes Offering

Feb 13, 2026, 4:15 PM EST - 7 weeks ago

Cencora Closes $3.0 Billion Senior Notes Offering

Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

Feb 10, 2026, 5:15 PM EST - 7 weeks ago

Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript

Feb 4, 2026, 1:10 PM EST - 2 months ago

Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript

Cencora beats quarterly profit estimates on strong demand for specialty medicines

Feb 4, 2026, 8:20 AM EST - 2 months ago

Cencora beats quarterly profit estimates on strong demand for specialty medicines

Cencora Reports Fiscal 2026 First Quarter Results

Feb 4, 2026, 6:30 AM EST - 2 months ago

Cencora Reports Fiscal 2026 First Quarter Results

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products

Jan 22, 2026, 9:00 AM EST - 2 months ago

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products

Cencora Elects Ellen Cooper to Its Board of Directors

Jan 22, 2026, 7:30 AM EST - 2 months ago

Cencora Elects Ellen Cooper to Its Board of Directors

Cencora: High-Growth Specialty Services Firm Disguised As A Distributor

Jan 21, 2026, 8:06 AM EST - 2 months ago

Cencora: High-Growth Specialty Services Firm Disguised As A Distributor

Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:36 PM EST - 2 months ago

Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

Jan 6, 2026, 4:30 PM EST - 3 months ago

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

Cencora to take majority control of OneOncology to expand cancer services

Dec 15, 2025, 7:11 AM EST - 3 months ago

Cencora to take majority control of OneOncology to expand cancer services

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Dec 15, 2025, 7:00 AM EST - 3 months ago

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities

Dec 3, 2025, 7:30 AM EST - 4 months ago

Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 3:33 PM EST - 4 months ago

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 12:53 PM EST - 4 months ago

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Cencora: Earnings Visibility Driving Re-Rating Potential

Nov 7, 2025, 2:05 PM EST - 5 months ago

Cencora: Earnings Visibility Driving Re-Rating Potential

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Nov 5, 2025, 4:01 PM EST - 5 months ago

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

Nov 5, 2025, 7:44 AM EST - 5 months ago

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain

Nov 5, 2025, 7:00 AM EST - 5 months ago

Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain

Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network

Nov 5, 2025, 7:00 AM EST - 5 months ago

Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

Nov 5, 2025, 6:30 AM EST - 5 months ago

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 5 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ABBV ADP AEP AIZ AOS ATO BDX

IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

Oct 16, 2025, 9:00 AM EDT - 6 months ago

IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.

Oct 14, 2025, 12:47 PM EDT - 6 months ago

The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.

MCK WFC

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

Oct 6, 2025, 4:30 PM EDT - 6 months ago

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 2:05 PM EDT - 7 months ago

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 6:02 PM EDT - 7 months ago

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 11:11 AM EDT - 7 months ago

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Aug 27, 2025, 4:15 PM EDT - 7 months ago

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Aug 12, 2025, 2:31 PM EDT - 8 months ago

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Aug 8, 2025, 5:08 PM EDT - 8 months ago

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 12:25 PM EDT - 8 months ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Cencora raises annual profit forecast on strong demand for specialty drugs

Aug 6, 2025, 7:51 AM EDT - 8 months ago

Cencora raises annual profit forecast on strong demand for specialty drugs

Cencora Reports Fiscal 2025 Third Quarter Results

Aug 6, 2025, 6:30 AM EDT - 8 months ago

Cencora Reports Fiscal 2025 Third Quarter Results

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

Jul 3, 2025, 7:30 AM EDT - 9 months ago

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 28, 2025, 7:30 AM EDT - 11 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

May 16, 2025, 8:37 AM EDT - 11 months ago

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

May 7, 2025, 2:06 PM EDT - 11 months ago

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 10:55 AM EDT - 11 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

Cencora Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 6:30 AM EDT - 11 months ago

Cencora Reports Fiscal 2025 Second Quarter Results

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

Apr 4, 2025, 3:42 PM EDT - 1 year ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM

These 15 stocks are the most profitable companies in the S&P 500

Mar 31, 2025, 7:35 AM EDT - 1 year ago

These 15 stocks are the most profitable companies in the S&P 500

AAPL ABBV AON BA CL CLX DVA

TalkMarkets
TalkMarkets Mar. 25 at 5:04 PM
The Growth Of Big Business: 1900-2020 $XOM $COR https://talkmarkets.com/article/b2346cd0-4c2c-45eb-9238-d7426cc25691
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 9:17 PM
$COR RSI: 24.02, MACD: -8.7204 Vol: 17.26, MA20: 350.55, MA50: 353.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 23 at 10:38 PM
$COR Share Price: $320.66 Contract Selected: Aug 21, 2026 $320 Calls Buy Zone: $39.10 – $48.30 Target Zone: $65.63 – $80.22 Potential Upside: 59% ROI Time to Expiration: 150 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CrazyChief
CrazyChief Mar. 23 at 8:47 PM
$OTLK $COR LET'S GO!! CENCORA PLEASE SCOOP UP OUTLOOK THERAPEUTICS!! 🙏🙏
0 · Reply
prismmarketview
prismmarketview Mar. 23 at 2:48 PM
$COR 🔵 Cencora just signed a $1.1B deal to acquire EyeSouth Partners' retina business — folding 400+ new physicians into its Retina Consultants of America platform. The numbers: physician count goes from ~300 to 700+. Retina market share jumps from ~1-2% to 3%+. Deal expected to be EPS-accretive within 12 months of close. Guidance reaffirmed. No FY2026 close assumed — so any contribution is pure upside to current estimates. Specialty care consolidation is real and $COR is leading it. 👁️ Regulatory approval pending. Not financial advice. https://prismmarketview.com/cencora-bets-1-1-billion-on-retina-care-and-the-math-makes-sense/
0 · Reply
50bps
50bps Mar. 17 at 1:53 PM
$COR 👀
1 · Reply
Ro_Patel
Ro_Patel Mar. 9 at 6:25 PM
Health Secretary RFK Jr plans to loosen restrictions on some peptides that the FDA previously prohibited compounding pharmacies from producing Kennedy wants to unban 14 of the 19 peptides that were placed on an FDA "do not formulate" list in 2023 Many physicians argue that many of them don't have sufficient evidence behind them to prove that they're safe & that they work https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks When the FDA added those peptides to its do-not-compound list, wellness entrepreneurs & compounding pharmacies pushed back, w/ some filing lawsuits against the FDA Kennedy blamed litigation for allowing him to only reinstate 14 of the 19 peptides that had been added to the list $MCK $COR $HIMS - $IPN $CTLT
1 · Reply
IN0V8
IN0V8 Mar. 3 at 6:09 PM
$COR 3/2 Buy Leerink Partners raises target price to $447 from $410
0 · Reply
RenkoTradingSystem
RenkoTradingSystem Feb. 28 at 12:11 PM
$COR 195 MIN 1% Renko Chart Only buy on the 1st and 2nd Green Bricks. 1/2 position on the 1st Green Brick. And the balance on the 2nd Green Brick. 1st 1/2 Entry: Pullback had at least 2-3 Red Bricks (clean, not choppy). 1st Green Brick appears. Stock Price is above EMA(20) and is rising. (Confirm at Daily Close; buy next Open) > Never enter on the 3rd Green Brick. 2nd Half Entry > Triggered within 2 Green Bricks of the first entry if no Red Bricks have appeared and EMA(20) is still rising. > If you miss buying on the 1st Green Brick: A 66% position on the 2nd Green Brick. (Confirm at Daily Close; buy next Open)
0 · Reply
DanFitz
DanFitz Feb. 28 at 2:12 AM
Here's your trade on Cencora $COR https://youtu.be/jbX0V_yHLHA
0 · Reply
RenkoTradingSystem
RenkoTradingSystem Feb. 27 at 11:51 AM
$COR Daily Elder Chart. At the bottom of the chart is the Industry and Sector. Industry is in an uptrend. Sector is somewhat flat but no Red Price Bars. COR is in an uptrend.
0 · Reply
PanicSeller8
PanicSeller8 Feb. 26 at 4:33 PM
$MCK $CAH $COR Buy and hold.
0 · Reply
RenkoTradingSystem
RenkoTradingSystem Feb. 26 at 3:08 PM
$COR 195 Minute 1% chart and Dow Jones Medical Supplies Index 195 Minute 1% chart Both have Green Bricks on their Weekly 1% Renko charts. Since I missed the 1st Green Brick, I'll be taking a 2/3% position today on the 2nd Green Brick. Stop-Loss: 2.5%. For financial advice, consult a professional. 🡲 I am not a financial consultant.
0 · Reply
PanicSeller8
PanicSeller8 Feb. 23 at 8:53 PM
$CAH $MCK $COR Overweight all these names. They print money and have stable demand no matter the economy.
0 · Reply
MilkingAlgosEveryMonday
MilkingAlgosEveryMonday Feb. 23 at 2:38 PM
$WGRX a lot investor don't aware of this baby $COR their business set up so good.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 19 at 10:32 PM
$COR Share Price: $359.09 Contract Selected: Jun 18, 2026 $360 Calls Buy Zone: $19.21 – $23.73 Target Zone: $33.60 – $41.07 Potential Upside: 65% ROI Time to Expiration: 118 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 2:18 PM
$COR’s strategic move: What does the MWI-Covetrus merger mean for investors? 🤔 💼 Unlocks $1.25B upfront cash + $800M in preferred equity + $1.45B in common equity, strengthening balance sheet 🔗 Retains 34.3% stake in combined company for long-term upside 📈 MWI's integration with Covetrus boosts efficiency & innovation See how this deal positions COR for future growth 👉 https://www.zacks.com/stock/news/2871829/cors-mwi-animal-health-to-merge-with-covetrus-in-35-billion-deal?cid=sm-stocktwits-2-2871829-body-34180&ADID=SYND_STOCKTWITS_TWEET_2_2871829_BODY_34180
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 1:18 PM
$COR makes a $3.5B move in animal health — strategic unlock or quiet power play? 🐾 Cencora is merging MWI Animal Health with Covetrus, retaining a 34.3% stake while unlocking capital and sharpening its focus on animal health growth. That’s not an exit — it’s a repositioning. Dig into what this deal could mean for shareholders 👉 https://www.zacks.com/stock/news/2871829/cors-mwi-animal-health-to-merge-with-covetrus-in-35-billion-deal?cid=sm-stocktwits-2-2871829-teaser-34165&ADID=SYND_STOCKTWITS_TWEET_2_2871829_TEASER_34165
0 · Reply
LandonCapital
LandonCapital Feb. 18 at 7:09 PM
$COR
0 · Reply
Estimize
Estimize Feb. 18 at 3:00 PM
Wall St is expecting 4.87 EPS for $COR Q2 [Reporting 05/06 BMO] http://www.estimize.com/intro/cor?chart=historical&metric_name=eps&utm_cont
0 · Reply
Moosedog97
Moosedog97 Feb. 18 at 2:42 PM
$COR selling MWI to $CVET
0 · Reply